• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva inks deal to test drugs with ProBioGen’s artificial lymph node tech

February 7, 2018 By Sarah Faulkner

ProBioGenTeva Pharmaceuticals (NYSE:TEVA) has inked a non-exclusive licensing deal to use ProBioGen‘s human artificial lymph node technology in the preclinical testing of the pharma company’s drug candidates.

ProBioGen, a contract developer and manufacturer based in Berlin, designed its 3D micro-organoid model for companies to use to predict the reactions that their drugs will provoke in the human immune system.

“With the complex, in vivo-like human artificial lymph node model we have demonstrated effects which were impossible to see in conventional models, bridging the existing gap between animal models and first-in-man applications,” ProBioGen’s chief scientific officer, Volker Sandig, said in prepared remarks. “We look much forward [sic] to this collaboration and the combined expertise on either side to develop the HuALN platform even further.”

The company’s HuALN model is based on a miniaturized bioreactor designed for the long-term cultivation of immune cells – the technology can culture cells for more than 4 weeks at a time. ProBioGen has argued that as biopharmaceuticals become more “species-specific,” animal models simply aren’t enough to predict a drug’s safety and efficacy.

The artificial lymph node tech is best suited to test vaccines, proteins and peptides, immune modulators and small molecules, according to the company.

The model includes human blood-derived dendritic cells, lymphocytes and stromal cells derived from mesenchymal stem cells, which are inoculated into the bioreactor’s 3D hydrogel matrix. When stimulated, the cells organize into immune-competent, micro-organoid structures.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Pharmaceuticals, Preclinical Trials, Wall Street Beat Tagged With: probiogen, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS